RenaissThera, a Bengaluru-based biotechnology company, has raised an undisclosed amount in its seed funding round backed by angel investors.
The funding will be used to accelerate the development of novel small-molecule therapies targeting GLP-1 and GIP receptors for Cardio-metabolic (CM) diseases, with an emphasis on diabetes and obesity.
Sudhir Nagarajan, Managing Director, said, “We thank all the investors in this round for their support and belief in our team and the promise of RenaissThera in delivering innovative medicines.”
With the successful close of its seed funding round, CEO Dr Ramkesh Meena said, “This milestone enables us to scale up and validate our early-stage pipeline in pre-clinical proof-of-concept studies and get ready for IND filing next year, propelling us closer to delivering life-changing, affordable therapies that address critical gaps in care.”
Founded in 2023 by Ramkesh Meena and Sudhir Nagarajan, RenaissTherais a biotechnology company dedicated to developing affordable, novel small-molecule targeted therapies leveraging AI platforms.
RenaissTherais focuses on high-unmet-need areas of prevalent diseases in key therapy areas such as Cardio-metabolic including diabetes and obesity indications. Leveraging Innovation Platform powered by GenAI tools, RenaissTherais identify small-molecule therapies for proven pathways, ensuring cutting-edge solutions for patients.
